ISSN 2564-7784 | E-ISSN 2564-7040
Original Article
Non-malignant late effects in lymphoma patients treated with autologous hematopoietic stem cell transplantation
1 Department of Internal Medicine, Murat State Hospital, Edirne, Turkey  
2 Department of Hematology, Eskişehir Osmangazi University, School of Medicine, Eskişehir, Turkey  
3 Department of Biostatistics, Eskişehir Osmangazi University, School of Medicine, Eskişehir, Turkey  
Gaziantep Med J 2017; 23: 106-110
DOI: 10.5152/EurJTher.2017.66
This article was viewed 49 times, downloaded 33 times

Key Words: Lymphoma, autologous hematopoietic stem cell transplantation, non-malignant, late effect
Abstract

Objective: Developments in transplantation procedures have led to an increase in the number of long-term survivors after hematopoietic stem cell transplantation (HSCT). In this study, we investigated non-malignant late side effects after autologous HSCT (AHSCT) in lymphoma patients.

 

Methods: Patients were evaluated for immune system, eye, lung, heart, liver, kidney, and endocrine function tests.

 

Results: Nine (26%) patients had absolute lymphopenia. Cataract was the only eye complication. Four (11.4%) patients had obstructive- and 8 (22.9%) had restrictive-type pulmonary function abnormalities. Only one patient had symptomatic heart failure. One patient developed renal failure. Fifty-three percent of male patients described impotence. The most frequent endocrine disorder was hypothyroidism. Five (14.2%) patients had osteoporosis.

 

Conclusion: There is not enough data on the non-malignant late effects after AHSCT. Although the lack of a control group is a limitation of our study, our results emphasize the importance of following AHSCT patients for non-malignant late effects of transplantation.

 

How to cite: Sırmatel P, Yılmaz H, Gündüz E. Non-malignant late effects in lymphoma patients treated with autologous hematopoietic stem cell transplantation. Eur J Ther 2017; 23: 106-10.

Key Words
Authors
All
Survey
AVES | Copyright © 2017 European Journal of Therapeutics | Latest Update: 04.10.2017